AMS has sued Biolitec in 2007 for violating a patent (the Davenport patent) which claims methods and devices for laser vaporization of prostate and other tissues.

AMS said that the District Court has granted a summary judgment of noninfringement to defendant Biolitec, stating that the accused device does not perform ‘photoselective vaporization of tissue.’

AMS said that the case will be sent to the District Court for further proceedings because of present ruling.

AMS president and chief executive officer Tony Bihl said that the Davenport patent is a reflection of AMS’ commitment to innovation in the field of laser therapy and they are pleased with the Court of Appeals’ decision and look forward to further proceedings in the trial court to determine infringement on our Davenport patent.